ArticleEpilepsia2025
Peripheral blood mononuclear cell secretome from patients with autoimmune encephalitis promotes seizures in vitro.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- WONOEP XVII appraisal: The immunopathogenesis of epilepsy.Epilepsia · 2026Review
- Peripheral blood mononuclear cell secretome from patients with autoimmune encephalitis promotes seizures in vitro.Epilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveAutoimmune encephalitis (AE) is characterized by inflammatory processes in the central nervous system and frequently presents with seizures. Even though an ictogenic potential has been shown for some antibodies against neuronal surface antigens (NSAbs), AE pathophysiology is complex, and NSAbs-independent mechanisms are likely to contribute to seizures. We investigated whether the secretome released by peripheral blood mononuclear cells (PBMCs) from AE patients contributes to seizure generation independently of NSAbs.
methodsPBMCs were isolated from 19 patients with AE (including both those with and those without detectable NSAbs) and 13 healthy volunteers. After 6 h in culture, the PBMC supernatant (secretome) was infused into a heterologous in vitro whole guinea pig brain preparation. Neurophysiological activity was monitored in the isolated in vitro guinea pig brain preparation during coperfusion of PBMC-derived supernatant (secretome) with the endotoxin lipopolysaccharide and human recombinant serum albumin, to induce and mimic, respectively, a mild functional blood-brain barrier impairment. Morphological analysis of ionized calcium-binding adapter molecule 1-positive glial cells was performed in these brains after the electrophysiological experiment. Secretome obtained after 6 h in culture was analyzed with the Multiplex ELLA array system for inflammatory mediator detection.
resultsElectrophysiological recordings and immunofluorescence analyses revealed that the secretome from PBMCs derived from AE patients induced seizurelike events and microglial activation in our in vitro brain preparation. Multiplex ELLA immunoassay analysis showed significantly lower concentration of interleukin (IL)-10, IL-1Ra, tumor necrosis factor-α, IL-2, and IL-6 in the secretome of PBMCs derived from AE patients compared to healthy subjects. IL-1β levels were comparable in the secretome of PBMCs derived from AE and healthy subjects. SIGNIFICANCE: Our findings suggest, for the first time, that peripheral inflammatory mediators could represent a trigger factor for seizure activity in AEs, beyond a possible antibody-mediated mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.